You are about to leave an AbbVie Canada site, a Web site maintained by AbbVie Corporation.
This link is provided for your convenience only. AbbVie Corporation takes no responsibility for the content of any Web site maintained by any third party and makes no representation as to the accuracy or completeness of any information contained on this or any subsequent link.
Do you wish to leave this site?
Yes No
Below is a list of all AbbVie clinical trials in Canada that you or someone you know might be interested in joining. Find what you’re looking for by using the filters to narrow down the results. You can also see the full list of conditions in which AbbVie deals here.
Condition :
Rheumatoid Arthritis
This is a multi center, randomized, double-blind, placebo-controlled phase 2 study in subjects with moderately to severely active rheumatoid arthritis on background methotrexate who have failed anti-Tumor Necrosis Factor (TNF) biologic therapy.
Condition :
Rheumatoid Arthritis, Musculoskeletal and Connective Tissue Diseases
A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects (PREDICTRA).
Condition :
Rheumatoid Arthritis
The purpose of this study is to describe the impact of treatment with adalimumab on work related productivity and economic burden in patients with Rheumatoid Arthritis (RA) treated in Canada.
Condition :
Rheumatoid Arthritis
A Canadian study to evaluate early use of adalimumab after methotrexate failure in early rheumatoid arthritis. The study hypothesis will verify if adalimumab effectively reduces joint damage in more patients when introduced earlier than in current practice.
Condition :
Rheumatoid Arthritis
The REACH study is conducted to describe the clinical effectiveness of adalimumab (HUMIRA) in subjects with moderately to severely active Rheumatoid Arthritis (RA) that are receiving anti-rheumatic treatments including adalimumab.
Condition :
Rheumatoid Arthritis
The comparison of safety and efficacy of upadacitinib versus abatacept in participants with rheumatoid arthritis on a stable background conventional synthetic Disease Modifying Anti-Rheumatic Drug (csDMARD) who have an inadequate response or intolerance to biologic DMARDs.
